n | Control | CRT | HR (95% CI) | p Value |
404 (%) | 409 (%) | |||
Death or CV hosp (main study) | 224 (55) | 159 (39) | 0.63 (0.51 to 0.77) | <0.001 |
Death or HF hosp (main study) | 191 (47) | 118 (29) | 0.54 (0.43 to 0.68) | <0.001 |
All-cause mortality* | 154 (38) | 101 (25) | 0.60 (0.47 to 0.77) | <0.001 |
Sudden death* | 54 (13.4) | 32 (7.8) | 0.54 (0.35 to 0.84) | 0.005 |
By 18 months | ||||
Investigator-assigned NYHA I/II | 151 (37) | 255 (62) | 0.36 (0.27 to 0.48) | <0.001 |
MLWHF Score ⩽35 | 166 (41) | 213 (52) | 0.64 (0.48 to 0.86) | 0.002 |
CRT implanted | 33 (8) | 390 (95) | N/A | N/A |
Numbers and percentages are shown for each outcome.
CRT, cardiac resynchronisation therapy; CV hosp, cardiovascular hospitalisation; HF hosp, heart failure hospitalisation; MLWHFQ, Minnesota living with heart failure questionnaire. N/A, analysis not appropriate.
*Includes data from both the main study and extension phase.